The content on this site is intended for healthcare professionals only
During a press conference at ESMO 2012 in Vienna, Dr Christophe Massard discusses a dose-escalation trial where 87% of 15 patients who received a novel androgen receptor agonist called ODM-201 experienced a PSA decrease at 12 weeks.
Understanding the use of PARPi combinations to treat patients with mCRPC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Durable responses in aRCC, how do we optimise treatment?
Darolutamide, androgen-deprivation therapy and docetaxel demonstrate promising efficacy mHSPC
EAU 2024: Bladder cancer latest
Enzalutamide monotherapy prolongs MFS compared to leuprolide alone in men with high-risk biochemically recurrent PC
